Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension

Current Topics in Developmental Biology

Volumn 67, Issue , 2005, Pages 251-284

  Schermuly, Ralph Theo ^a   Ghofrani, Hossein Ardeschir ^a   Weissmann, Norbert ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645925377     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0070-2153(05)67008-1     Document Type: Chapter

References (170)

1. Abe Y., Tatsumi K., Sugito K., Ikeda Y., Kimura H., and Kuriyama T. Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension. J. Cardiovasc. Pharmacol. 37 (2001) 239-251
2. Ahn H.S., Foster M., Cable M., Pitts B.J., and Sybertz E.J. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv. Exp. Med. Biol. 308 (1991) 191-197
3. Aranda M., Bradford K.K., and Pearl R.G. Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertension. Anesth. Analg. 89 (1999) 152-158
4. Archer S.L., Chesler E., Cohn J.N., and Weir E.K. ZK 36-374, a stable analog of prostacyclin, prevents acute hypoxic pulmonary hypertension in the dog. J. Am. Coll. Cardiol. 8 (1986) 1189-1194
5. Badesch D.B., McLaughlin V.V., Delcroix M., Vizza C.D., Olschewski H., Sitbon O., and Barst R.J. Prostanoid therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43 (2004) 56S-61S
6. Badesch D.B., Orton E.C., Zapp L.M., Westcott J.Y., Hester J., Voelkel N.F., and Stenmark K.R. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 1 (1989) 489-498
7. Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., and Naylor A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 159 (1998) 2164-2171
8. Beavo J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
9. Bloch W., Klotz T., Sedlaczek P., Zumbe J., Engelmann U., and Addicks K. Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum. Urol. Res. 26 (1998) 129-135
10. Blumberg F.C., Lorenz C., Wolf K., Sandner P., Riegger G.A., and Pfeifer M. Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension. Cardiovasc. Res. 55 (2002) 171-177
11. Bonnell M.R., Urdaneta F., Kirby D.S., Valdez N.R., Beaver T.M., and Lobato E.B. Effects of sildenafil analogue UK 343-664 on a porcine model of acute pulmonary hypertension. Ann. Thorac. Surg. 77 (2004) 238-242
12. Booke M., Bradford D.W., Hinder F., Harper D., Brauchle R.W., Traber L.D., and Traber D.L. Effects of inhaled nitric oxide and nebulized prostacyclin on hypoxic pulmonary vasoconstriction in anesthetized sheep. Crit. Care Med. 24 (1996) 1841-1848
13. Braner D.A., Fineman J.R., Chang R., and Soifer S.J. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 264 (1993) H252-H258
14. Burch G.H., Jensen L.R., Pappas J., Hammond E.H., Banner Jr. W., and Shaddy R.E. Growth factor expression and effects of amrinone in monocrotaline-induced pulmonary hypertension in rats. Biochem. Mol. Med. 58 (1996) 204-210
15. Cheitlin M.D., Hutter Jr. A.M., Brindis R.G., Ganz P., Kaul S., Russell Jr. R.O., and Zusman R.M. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 99 (1999) 168-177
16. Chen E.P., Bittner H.B., Davis R.D., and Van T.P. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. J. Heart Lung Transplant. 17 (1998) 669-678
17. Chen E.P., Bittner H.B., Davis Jr. R.D., and Van III T.P. Effects of nitric oxide after cardiac transplantation in the setting of recipient pulmonary hypertension. Ann. Thorac. Surg. 63 (1997) 1546-1555
18. Chen E.P., Bittner H.B., Tull F., Biswas S.S., Davis R.D., and Van T.P. An adult canine model of chronic pulmonary hypertension for cardiopulmonary transplantation. J. Heart Lung Transplant. 16 (1997) 538-547
19. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard G.R., Groves B.M., and Loyd J.E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension [see comments]. N. Engl. J. Med. 327 (1992) 70-75
20. Clarke W.R., Uezono S., Chambers A., and Doepfner P. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm. Pharmacol. 7 (1994) 81-89
21. Cohen A.H., Hanson K., Morris K., Fouty B., McMurty I.F., Clarke W., and Rodman D.M. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 97 (1996) 172-179
22. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63 (1999) 1-38
23. Conti M., Nemoz G., Sette C., and Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16 (1995) 370-389
24. Cortijo J., Villagrasa V., Navarrete C., Sanz C., Berto L., Michel A., Bonnet P.A., and Morcillo E.J. Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: Comparison with rolipram, SKF94120, and levcromakalim. Br. J. Pharmacol. 119 (1996) 99-106
25. Coste H., and Grondin P. Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem. Pharmacol. 50 (1995) 1577-1585
26. Cowan K.N., Heilbut A., Humpl T., Lam C., Ito S., and Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 6 (2000) 698-702
27. Crilley T.K., Wanstall J.C., and Bonnet P.A. Vasorelaxant effects of SCA40 (a phosphodiesterase III inhibitor) in pulmonary vascular preparations in rats. Clin. Exp. Pharmacol. Physiol. 25 (1998) 355-360
28. Czer G.T., Marsh J., Konopka R., and Moser K.M. Low-dose PGI2 prevents monocrotaline-induced thromboxane production and lung injury. J. Appl. Physiol. 60 (1986) 464-471
29. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., and Kernis J.T. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115 (1991) 343-349
30. Dagher E., Dumont L., Chartrand C., and Blaise G. Effects of PGE1 in experimental vasoconstrictive pulmonary hypertension. Eur. Surg. Res. 25 (1993) 65-73
31. Deb B., Bradford K., and Pearl R.G. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit. Care Med. 28 (2000) 795-799
32. Dervin G., and Calvin Jr. J.E. Role of prostaglandin E1 in reducing pulmonary vascular resistance in an experimental model of acute lung injury. Crit. Care Med. 18 (1990) 1129-1133
33. Doh H., Shin C.Y., Son M., Ko J.I., Yoo M., Kim S.H., and Kim W.B. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch. Pharm. Res. 25 (2002) 873-878
34. Dumont L., and Dagher E. Effects of amrinone and dobutamine on PGF2 alpha-induced pulmonary hypertension in dogs. Eur. Surg. Res. 26 (1994) 201-209
35. Durmowicz A.G., and Stenmark K.R. Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr. Rev. 20 (1999) e91-e102
36. Eddahibi S., Raffestin B., Le Monnier de Gouville A.C., and Adnot S. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br. J. Pharmacol. 125 (1998) 681-688
37. Ensley R.D., and Rubin L.J. Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: Evidence for a prostaglandin-mediated mechanism. Prostaglandins Leukot. Med. 18 (1985) 95-104
38. Fawcett L., Baxendale R., Stacey P., McGrouther C., Harrow I., Soderling S., Hetman J., Beavo J.A., and Phillips S.C. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Natl. Acad. Sci. USA 97 (2000) 3702-3707
39. Fike C.D., Kaplowitz M.R., and Pfister S.L. Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs. Am. J. Physiol Lung Cell Mol. Physiol. 284 (2003) L316-L323
40. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., and Cheng J.B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273 (1998) 15559-15564
41. Fishman A.P. Hypoxia on the pulmonary circulation. How and where it acts. Circ. Res. 38 (1976) 221-231
42. Ford W.D., Sen S., Barker A.P., and Lee C.M. Pulmonary hypertension in lambs with congenital diaphragmatic hernia: Vasodilator prostaglandins, isoprenaline, and tolazoline. J. Pediatr. Surg. 25 (1990) 487-491
43. Foubert L., De W.D., Mareels K., Van B.Y., Reyntjens K., Mortier E., and Van N.G. Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets. Pediatr. Res. 52 (2002) 730-736
44. Foubert L., De W.D., Reyntjens K., Van B.Y., De S.F., Van N.G., and Mortier E. Intermittent nitric oxide combined with intravenous dipyridamole in a piglet model of acute pulmonary hypertension. Anesth. Analg. 97 (2003) 1497-1500
45. Geraci M.W., Gao B., Shepherd D.C., Moore M.D., Westcott J.Y., Fagan K.A., Alger L.A., Tuder R.M., and Voelkel N.F. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J. Clin. Invest. 103 (1999) 1509-1515
46. Ghofrani H.A., Pepke-Zaba J., Barbera J.A., Channick R., Keogh A.M., Gomez-Sanchez M.A., Kneussl M., and Grimminger F. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43 (2004) 68S-72S
47. Ghofrani H.A., Voswinckel R., Reichenberger F., Olschewski H., Haredza P., Karadas B., Schermuly R.T., Weissmann N., Seeger W., and Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J. Am. Coll. Cardiol. 44 (2004) 1488-1496
48. Ghofrani H.A., Rose F., Schermuly R.T., Olschewski H., Wiedemann R., Kreckel A., Weissmann N., Ghofrani S., Enke B., Seeger W., and Grimminger F. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42 (2003) 158-164
49. Ghofrani H.A., Schermuly R.T., Rose F., Wiedemann R., Kohstall M.G., Kreckel A., Olschewski H., Weissmann N., Enke B., Ghofrani S., Seeger W., and Grimminger F. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 167 (2003) 1139-1141
50. Ghofrani H.A., Rose F., Schermuly R.T., Olschewski H., Wiedemann R., Weissmann N., Schudt C., Tenor H., Seeger W., and Grimminger F. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit. Care Med. 30 (2002) 2489-2492
51. Ghofrani H.A., Wiedemann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., Seeger W., and Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136 (2002) 515-522
52. Ghofrani H.A., Wiedemann R., Rose F., Schermuly R.T., Olschewski H., Weissmann N., Gunther A., Walmrath D., Seeger W., and Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial. Lancet 360 (2002) 895-900
53. Gillespie P.G., and Beavo J.A. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948. Mol. Pharmacol. 36 (1989) 773-781
54. Giordano D., De Stefano M.E., Citro G., Modica A., and Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim. Biophys. Acta 1539 (2001) 16-27
55. Gresser U., and Gleiter C.H. Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil-Review of the literature. Eur. J. Med. Res. 7 (2002) 435-446
56. Grimminger F., Spriestersbach R., Weissmann N., Walmrath D., and Seeger W. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J. Appl. Physiol. 78 (1995) 1509-1515
57. Hagiwara M., Endo T., and Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 33 (1984) 453-457
58. Hanasato N., Oka M., Muramatsu M., Nishino M., Adachi H., and Fukuchi Y. E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am. J. Physiol. 277 (1999) L225-L232
59. Hanson K.A., Burns F., Rybalkin S.D., Miller J.W., Beavo J., and Clarke W.R. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am. J. Respir. Crit. Care Med. 158 (1998) 279-288
60. Harrison S.A., Reifsnyder D.H., Gallis B., Cadd G.G., and Beavo J.A. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: A receptor for new cardiotonic drugs. Mol. Pharmacol. 29 (1986) 506-514
61. Hatori N., Takeshima S., Aoki T., Shimizu M., Hinokiyama K., Haraguchi S., Ochi M., Yoshizu H., and Tanaka S. Effectiveness of prostaglandin E1 on pulmonary hypertension and right cardiac function induced by single-lung ventilation and hypoventilation. Ann. Thorac. Cardiovasc. Surg. 6 (2000) 236-241
62. Hayashi M., Matsushima K., Ohashi H., Tsunoda H., Murase S., Kawarada Y., and Tanaka T. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 250 (1998) 751-756
63. Haynes Jr. J., Kithas P.A., Taylor A.E., and Strada S.J. Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am. J. Physiol. 261 (1991) H487-H492
64. Hetman J.M., Soderling S.H., Glavas N.A., and Beavo J.A. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc. Natl. Acad. Sci. USA 97 (2000) 472-476
65. Hidaka H., and Endo T. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase-Basic and potential clinical applications. Adv. Cyclic. Nucleotide. Protein Phosphorylation. Res. 16 (1984) 245-259
66. Hill L.L., and Pearl R.G. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J. Appl. Physiol. 86 (1999) 1160-1164
67. Holzmann A., Manktelow C., Weimann J., Bloch K.D., and Zapol W.M. Inhibition of lung phosphodiesterase improves responsiveness to inhaled nitric oxide in isolated-perfused lungs from rats challenged with endotoxin. Intensive Care Med. 27 (2001) 251-257
68. Hoshikawa Y., Voelkel N.F., Gesell T.L., Moore M.D., Morris K.G., Alger L.A., Narumiya S., and Geraci M.W. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am. J. Respir. Crit. Care Med. 164 (2001) 314-318
69. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., Christman B.W., Weir E.K., Eickelberg O., Voelkel N.F., and Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43 (2004) 13S-24S
70. Huxtable R.J. Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacol. Ther. 47 (1990) 371-389
71. Ichinose F., Adrie C., Hurford W.E., Bloch K.D., and Zapol W.M. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 88 (1998) 410-416
72. Ichinose F., Erana-Garcia J., Hromi J., Raveh Y., Jones R., Krim L., Clark M.W., Winkler J.D., Bloch K.D., and Zapol W.M. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit. Care Med. 29 (2001) 1000-1005
73. Inoue H., Yano K., Noto T., Takagi M., Ikeo T., and Kikkawa K. Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats. Biol. Pharm. Bull. 25 (2002) 1422-1426
74. Ishibe Y., Nakamura M., Umeda T., Izumi T., Shiokawa Y., and Suekane K. [Effects of prostacyclin (PGI2) on the hypoxic pulmonary vasoconstriction in dogs]. Masui 38 (1989) 1619-1626
75. Itoh T., Nagaya N., Fujii T., Iwase T., Nakanishi N., Hamada K., Kangawa K., and Kimura H. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 169 (2004) 34-38
76. Jacobitz S., McLaughlin M.M., Livi G.P., Burman M., and Torphy T.J. Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. 50 (1996) 891-899
77. Jeffery T.K., and Wanstall J.C. Pulmonary vascular remodeling: A target for therapeutic intervention in pulmonary hypertension. Pharmacol. Ther. 92 (2001) 1-20
78. Kang K.K., Ahn G.J., Sohn Y.S., Ahn B.O., and Kim W.B. DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats. Arch. Pharm. Res. 26 (2003) 612-619
79. Kang K.K., Ahn G.J., Sohn Y.S., Ahn B.O., and Kim W.B. DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. J. Int. Med. Res. 31 (2003) 517-528
80. Kariya T., Wille L.J., and Dage R.C. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043. J. Cardiovasc. Pharmacol. 4 (1982) 509-514
81. Kato R., Sato J., and Nishino T. Milrinone decreases both pulmonary arterial and venous resistances in the hypoxic dog. Br. J. Anaesth. 81 (1998) 920-924
82. Kato S., Kishiro I., Sugimura H., Machida S., Fuse D., and Kaneko N. Changes of sequestered leukocytes and platelets by inhalation prostaglandin E(1) in the pulmonary microvasculature of rats with monocrotaline-induced pulmonary hypertension. J. Vasc. Res. 39 (2002) 83-87
83. Kato S., Sugimura H., Kishiro I., Machida M., Suzuki H., and Kaneko N. Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with monocrotaline-induced pulmonary hypertension. Exp. Lung Res. 28 (2002) 265-273
84. Kauffman R.F., Crowe V.G., Utterback B.G., and Robertson D.W. LY195115: A potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol. Pharmacol. 30 (1986) 609-616
85. Kavanagh B.P., Thompson J.S., and Pearl R.G. Inhibition of endogenous nitric oxide synthase potentiates nitrovasodilators in experimental pulmonary hypertension. Anesthesiology 85 (1996) 860-866
86. Kinsella B.T., O'Mahony D.J., and Fitzgerald G.A. The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J. Pharmacol. Exp. Ther. 281 (1997) 957-964
87. Kleen M., Habler O., Hofstetter C., Pusch R., Mueller M., Welte M., and Zwissler B. Efficacy of inhaled prostanoids in experimental pulmonary hypertension. Crit. Care Med. 26 (1998) 1103-1109
88. Kodama K., and Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J. Pharmacol. Exp. Ther. 290 (1999) 748-752
89. Kotera J., Fujishige K., Michibata H., Yuasa K., Kubo A., Nakamura Y., and Omori K. Characterization and effects of methyl-2-(4-aminophenyl)-1, 2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem. Pharmacol. 60 (2000) 1333-1341
90. Kothapalli D., Stewart S.A., Smyth E.M., Azonobi I., Pure E., and Assoian R.K. Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol. Pharmacol. 64 (2003) 249-258
91. Leffler C.W., and Passmore J.C. Contribution of prostaglandins to the regulation of pulmonary vascular resistance in adult cats and dogs. Prostaglandins Med. 3 (1979) 343-360
92. Li R.C., Cindrova-Davies T., Skepper J.N., and Sellers L.A. Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ. Res. 94 (2004) 759-767
93. MacLean M.R., Johnston E.D., Mcculloch K.M., Pooley L., Houslay M.D., and Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension. J. Pharmacol. Exp. Ther. 283 (1997) 619-624
94. Masuoka H., Ito M., Sugioka M., Kozeki H., Konishi T., Tanaka T., and Nakano T. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent. Biochem. Biophys. Res. Commun. 190 (1993) 412-417
95. Matot I., and Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 125 (2004) 644-651
96. Maurice D.H., Palmer D., Tilley D.G., Dunkerley H.A., Netherton S.J., Raymond D.R., Elbatarny H.S., and Jimmo S.L. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64 (2003) 533-546
97. Max M., Kuhlen R., Dembinski R., and Rossaint R. Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension. Intensive Care Med. 25 (1999) 1147-1154
98. McLean R.F., Prielipp R.C., Rosenthal M.H., and Pearl R.G. Vasodilator therapy in microembolic porcine pulmonary hypertension. Anesth. Analg. 71 (1990) 35-41
99. Mery P.F., Pavoine C., Pecker F., and Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol. Pharmacol. 48 (1995) 121-130
100. Miyata M., Ueno Y., Sekine H., Ito O., Sakuma F., Koike H., Nishio S., Nishimaki T., and Kasukawa R. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. J. Cardiovasc. Pharmacol. 27 (1996) 20-26
101. Murray F., MacLean M.R., and Pyne N.J. An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension. Br. J. Pharmacol. 138 (2003) 1313-1319
102. Nagamine J., Hill L.L., and Pearl R.G. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit. Care Med. 28 (2000) 2420-2424
103. Nagaya N., Yokoyama C., Kyotani S., Shimonishi M., Morishita R., Uematsu M., Nishikimi T., Nakanishi N., Ogihara T., Yamagishi M., Miyatake K., Kaneda Y., and Tanabe T. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 102 (2000) 2005-2010
104. Nangle M.R., Cotter M.A., and Cameron N.E. An in vitro study of corpus cavernosum and aorta from mice lacking the inducible nitric oxide synthase gene. Nitric Oxide 9 (2003) 194-200
105. Nemecek G.M., and Honeyman T.W. The role of cyclic nucleotide phosphodiesterase in the inhibition of cyclic AMP accumulation by carbachol and phosphatidate. J. Cyclic. Nucleotide. Res. 8 (1982) 395-408
106. Ohnishi M., Oka M., Muramatsu M., Sato K., Kira S., and Fukuchi Y. E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs. J. Cardiovasc. Pharmacol. 33 (1999) 619-624
107. Ono S., Tanita T., Hoshikawa Y., Song C., Maeda S., Tabata T., Noda M., Ueda S., Ashino Y., and Fujimura S. [Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension]. Nihon Kyobu Shikkan Gakkai Zasshi 33 (1995) 862-867
108. Ono S., and Voelkel N.F. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J. Appl. Physiol. 71 (1991) 2483-2492
109. Owall A., Davilen J., and Sollevi A. Influence of adenosine and prostacyclin on hypoxia-induced pulmonary hypertension in the anaesthetized pig. Acta Anaesthesiol. Scand. 35 (1991) 350-354
110. Pearl R.G., and Siegel L.C. Effects of prostaglandin E1 and hydralazine on the longitudinal distribution of pulmonary vascular resistance during vasoconstrictor pulmonary hypertension in sheep. Anesthesiology 76 (1992) 106-112
111. Philips III J.B., Lyrene R.K., McDevitt M., Perlis W., Satterwhite C., and Cassady G. Prostaglandin D2 inhibits hypoxic pulmonary vasoconstriction in neonatal lambs. J. Appl. Physiol. 54 (1983) 1585-1589
112. Phillips P.G., Long L., Wilkins M.R., and Morrell N.W. Cyclic AMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogues in hypoxic pulmonary vascular remodeling. Am. J. Physiol. Lung Cell Mol. Physiol. 288 (2004) L103-L115
113. Prie S., Leung T.K., Cernacek P., Ryan J.W., and Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J. Pharmacol. Exp. Ther. 282 (1997) 1312-1318
114. Prielipp R.C., McLean R., Rosenthal M.H., and Pearl R.G. Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. Crit. Care Med. 19 (1991) 60-67
115. Prielipp R.C., Rosenthal M.H., and Pearl R.G. Vasodilator therapy in vasoconstrictor-induced pulmonary hypertension in sheep. Anesthesiology 68 (1988) 552-558
116. Rabe K.F., Tenor H., Dent G., Schudt C., Liebig S., and Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: Identification and characterization. Am. J. Physiol. 264 (1993) L458-L464
117. Rondelet B., Kerbaul F., Van B.R., Motte S., Fesler P., Hubloue I., Remmelink M., Brimioulle S., Salmon I., Ketelslegers J.M., and Naeije R. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: Effects of sildenafil therapy. Circulation 110 (2004) 2220-2225
118. Rosenberg H.C., and Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am. J. Physiol. 255 (1988) H1484-H1491
119. Ruppert D., and Weithmann K.U. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro. Life Sci. 31 (1982) 2037-2043
120. Saeki T., Adachi H., Takase Y., Yoshitake S., Souda S., and Saito I. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J. Pharmacol. Exp. Ther. 272 (1995) 825-831
121. Saenz d.T.I., Angulo J., Cuevas P., Fernandez A., Moncada I., Allona A., Lledo E., Korschen H.G., Niewohner U., Haning H., Pages E., and Bischoff E. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. 13 (2001) 282-290
122. Sakuma F., Miyata M., and Kasukawa R. Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats. Lung 177 (1999) 77-88
123. Schermuly R.T., Ghofrani H.A., Enke B., Weissmann N., Grimminger F., Seeger W., Schudt C., and Walmrath D. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am. J. Respir. Crit. Care Med. 160 (1999) 1500-1506
124. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Samidurai A., Pullamsetti S., Weissmann N., Schudt C., Ermert L., Seeger W., and Grimminger F. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. 94 (2004) 1101-1108
125. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Yilmaz H., Butrous G., Ermert L., Ermert M., Weissmann N., Rose F., Guenther A., Walmrath D., Seeger W., and Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 169 (2004) 39-45
126. Schermuly R.T., Krupnik E., Tenor H., Schudt C., Weissmann N., Rose F., Grimminger F., Seeger W., Walmrath D., and Ghofrani H.A. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am. J. Respir. Crit. Care Med. 164 (2001) 1694-1700
127. Schermuly R.T., Leuchte H., Ghofrani H.A., Weissmann N., Rose F., Kohstall M., Olschewski H., Schudt C., Grimminger F., Seeger W., and Walmrath D. Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur. Respir. J. 22 (2003) 342-347
128. Schermuly R.T., Roehl A., Weissmann N., Ghofrani H.A., Leuchte H., Grimminger F., Seeger W., and Walmrath D. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 281 (2001) L1361-L1368
129. Schermuly R.T., Roehl A., Weissmann N., Ghofrani H.A., Schudt C., Tenor H., Grimminger F., Seeger W., and Walmrath D. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J. Pharmacol. Exp. Ther. 292 (2000) 512-520
130. Schermuly R.T., Weissmann N., Enke B., Ghofrani H.A., Forssmann W.G., Grimminger F., Seeger W., and Walmrath D. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: Synergism upon coapplication. Am. J. Respir. Cell Mol. Biol. 25 (2001) 219-225
131. Schudt C., Winder S., Eltze M., Kilian U., and Beume R. Zardaverine: A cyclic AMP-specific PDE III/IV inhibitor. Agents Actions Suppl. 34 (1991) 379-402
132. Sebkhi A., Strange J.W., Phillips S.C., Wharton J., and Wilkins M.R. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107 (2003) 3230-3235
133. Shaul P.W., Kinane B., Farrar M.A., Buja L.M., and Magness R.R. Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery. Alterations after prolonged hypoxia in the rat. J. Clin. Invest. 88 (1991) 447-455
134. Shekerdemian L.S., Ravn H.B., and Penny D.J. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr. Res. 55 (2004) 413-418
135. Shekerdemian L.S., Ravn H.B., and Penny D.J. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am. J. Respir. Crit. Care Med. 165 (2002) 1098-1102
136. Sheppard H., Wiggan G., and Tsien W.H. Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues. Adv. Cyclic. Nucleotide. Res. 1 (1972) 103-112
137. Soderling S.H., Bayuga S.J., and Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. 273 (1998) 15553-15558
138. Soderling S.H., Bayuga S.J., and Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA 96 (1999) 7071-7076
139. Sprague R.S., Stephenson A.H., and Lonigro A.J. Prostaglandin I2 supports blood flow to hypoxic alveoli in anesthetized dogs. J. Appl. Physiol. 56 (1984) 1246-1251
140. Spriestersbach R., Grimminger F., Weissmann N., Walmrath D., and Seeger W. On-line measurement of nitric oxide generation in buffer-perfused rabbit lungs. J. Appl. Physiol. 78 (1995) 1502-1508
141. Staub N.C. Site of hypoxic pulmonary vasoconstriction. Chest 88 (1985) 240S-245S
142. Sudo T., Tachibana K., Toga K., Tochizawa S., Inoue Y., Kimura Y., and Hidaka H. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol. 59 (2000) 347-356
143. Suhara H., Sawa Y., Fukushima N., Kagisaki K., Yokoyama C., Tanabe T., Ohtake S., and Matsuda H. Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats. J. Thorac. Cardiovasc. Surg. 123 (2002) 855-861
144. Takahashi T., Kanda T., Inoue M., Suzuki T., Kobayashi I., Kodama K., and Nagai R. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci. 59 (1996) L-7
145. Takahashi T., Kanda T., Sumino H., Inoue M., Sato K., Sakamaki T., Kobayashi I., Iwamoto A., and Nagai R. Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Res. Exp. Med. (Berl) 197 (1998) 319-328
146. Tanaka H., Tajimi K., Matsumoto A., and Kobayashi K. Effects of milrinone on lung water content in dogs with acute pulmonary hypertension. J. Pharmacol. Toxicol. Methods 28 (1992) 201-208
147. Torphy T.J., and Cieslinski L.B. Characterization and selective inhibition ofcyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol. Pharmacol. 37 (1990) 206-214
148. Tuder R.M., Cool C.D., Geraci M.W., Wang J., Abman S.H., Wright L., Badesch D., and Voelkel N.F. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159 (1999) 1925-1932
149. Ueno M., Miyauchi T., Sakai S., Goto K., and Yamaguchi I. Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats. J. Cardiovasc. Pharmacol. 36 (2000) S305-S310
150. Ueno M., Miyauchi T., Sakai S., Yamauchi-Kohno R., Goto K., and Yamaguchi I. A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats. J. Am. Coll. Cardiol. 40 (2002) 175-181
151. Van Obbergh L.J., Charbonneau M., and Blaise G. Combination of inhaled nitric oxide with i.v. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension. Br. J. Anaesth. 77 (1996) 227-231
152. Voelkel N.F. Mechanisms of hypoxic pulmonary vasoconstriction. Am. Rev. Respir. Dis. 133 (1986) 1186-1195
153. Von Euler U.S., and Liljestrand G. Observations on the pulmonary arterial bloodpressure in the cat. Acta Physiol. Scand. 12 (1946) 301-320
154. Wagner R.S., Smith C.J., Taylor A.M., and Rhoades R.A. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J. Pharmacol. Exp. Ther. 282 (1997) 1650-1657
155. Walmrath D., Schermuly R., Pilch J., Grimminger F., and Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur. Respir. J. 10 (1997) 1084-1092
156. Watanabe N., Adachi H., Takase Y., Ozaki H., Matsukura M., Miyazaki K., Ishibashi K., Ishihara H., Kodama K., Nishino M., Kakiki M., and Kabasawa Y. 4-(3-Chloro- 4-methoxybenzyl)aminophthalazines: Synthesis and inhibitory activity toward phosphodiesterase 5. J. Med. Chem. 43 (2000) 2523-2529
157. Weimann J., Ullrich R., Hromi J., Fujino Y., Clark M.W., Bloch K.D., and Zapol W.M. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92 (2000) 1702-1712
158. Weir E.K., Reeves J.T., and Grover R.F. Prostaglandin E1 inhibits the pulmonary vascular pressor response to hypoxia and prostaglandin F2alpha. Prostaglandins 10 (1975) 623-631
159. Weissmann N., Nollen M., Gerigk B., Ardeschir G.H., Schermuly R.T., Gunther A., Quanz K., Fink L., Hanze J., Rose F., Seeger W., and Grimminger F. Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: Effects of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H931-H938
160. Weissmann N., Voswinckel R., Hardebusch T., Rosseau S., Ghofrani H.A., Schermuly R., Seeger W., and Grimminger F. Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. Am.J. Physiol. 276 (1999) L90-L95
161. Weissmann N., Voswinckel R., Tadic A., Hardebusch T., Ghofrani H.A., Schermuly R.T., Seeger W., and Grimminger F. Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs. Am. J. Respir. Cell Mol. Biol. 23 (2000) 222-227
162. Wells J.N., and Miller J.R. Methylxanthine inhibitors of phosphodiesterases. Methods Enzymol. 159 (1988) 489-496
163. Welte M., Zwissler B., Habazettl H., and Messmer K. PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur. Surg. Res. 25 (1993) 329-340
164. Wharton J., Davie N., Upton P.D., Yacoub M.H., Polak J.M., and Morrell N.W. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 102 (2000) 3130-3136
165. Wilkens H., Guth A., Konig J., Forestier N., Cremers B., Hennen B., Bohm M., and Sybrecht G.W. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 (2001) 1218-1222
166. Wilson D.W., Segall H.J., Pan L.C., Lame M.W., Estep J.E., and Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev. Toxicol. 22 (1992) 307-325
167. Yuki H., Sato S., Arisaka Y., Kato S., and Tomoike H. Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats. Tohoku J. Exp. Med. 173 (1994) 371-375
168. Zhao L., Mason N.A., Morrell N.W., Kojonazarov B., Sadykov A., Maripov A., Mirrakhimov M.M., Aldashev A., and Wilkins M.R. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104 (2001) 424-428
169. Zhao L., Mason N.A., Strange J.W., Walker H., and Wilkins M.R. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 107 (2003) 234-237
170. Zwissler B., Welte M., and Messmer K. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J. Cardiothorac. Vasc. Anesth. 9 (1995) 283-289